$4,150.78 travel Payment -- Gilead Sciences to Dr. Heather Mitchell
Gilead Sciences Pays Pulmonologist $4,150 for Rinvoq-Related Travel
This page provides a detailed analysis of a $4,150.78 travel payment from Gilead Sciences to Dr. Heather Mitchell. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $4,150.78 |
| Payment Type | travel |
| Payment Nature | Travel and Lodging |
| Pharmaceutical Company | Gilead Sciences |
| Physician | Dr. Heather Mitchell |
| NPI Number | 1962366663 |
| Physician Specialty | Pulmonology |
| Location | Worcester, MA |
| Date of Payment | 2025-03-29 |
| Related Drug/Device | Rinvoq |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Gilead Sciences made a $4.2K travel payment to Heather Mitchell, a Pulmonology specialist in Worcester, MA. The payment was associated with Rinvoq. The payment of $4,150.78 to Dr. Heather Mitchell from Gilead Sciences for travel and lodging related to Rinvoq is a significant expense. This payment occurred on March 29, 2025, indicating a recent engagement between the pharma company and the physician. The payment was made to a Pulmonology specialist, suggesting a focus on respiratory conditions or treatments.
Patient Guidance: What This Payment Means for You
This payment was for travel and lodging expenses related to a pharmaceutical product. It's important to understand how such expenses might influence medical recommendations. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
For Pulmonology, travel and lodging payments can vary widely depending on the nature of the educational event or research. This amount may be moderate to high depending on the duration and location of the travel.
Regulatory Context: Sunshine Act Requirements
Payments to physicians for travel and lodging must be reported under the Sunshine Act to ensure transparency in the relationships between healthcare providers and pharmaceutical companies.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharma-payments
- physician-compensation
- travel-expenses
- drug-promotion
- pulmonology
- gilead-sciences
- rinvoq
Understanding travel Payments
Travel and lodging payments cover transportation and accommodation expenses for physicians attending conferences, advisory board meetings, or speaking engagements sponsored by pharmaceutical companies. These payments can be substantial, particularly for international travel or multi-day events.
Frequently Asked Questions About This Payment
What was this $4.2K payment for?
This was a travel payment of $4.2K from Gilead Sciences to Heather Mitchell, categorized as "Travel and Lodging". It was associated with Rinvoq. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Heather Mitchell accept pharmaceutical money?
Yes, Heather Mitchell received this $4.2K payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Heather Mitchell's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this travel payment?
A travel payment of $4.2K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Pulmonology?
To compare this payment against Pulmonology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Pulmonology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Heather Mitchell's relationship with Gilead Sciences?
The payment amount is substantial for travel and lodging, warranting further investigation into the specifics of the trip. This $4.2K travel payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Pulmonology?
The payment is tied to a specific drug, Rinvoq, suggesting educational or promotional activities.
What should patients do after learning about this payment?
This payment was for travel and lodging expenses related to a pharmaceutical product. It's important to understand how such expenses might influence medical recommendations.
What else should I know about this travel payment?
The physician's specialty, Pulmonology, aligns with potential uses of Rinvoq in treating certain respiratory diseases.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.